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aTATE-OF-THE-ART PAPER2293Defining Procedural Success for Catheter Ablation of AFemosthenes Katritsis, Faisal M. Merchant, Theofanie Mela, Jagmeet P. Singh, E. Kevin Heist,
ntonis A. Armoundas
he single procedure efficacy for catheter ablation of atrial fibrillation (AF) remains below
0% for patients with structural heart disease or long-standing persistent AF. This had led to
he paradigm of “triggers” and “substrate;” eliminating triggers may lead to success in patients
ith paroxysmal AF, but those with chronic AF may also require modification of the
ubstrate. However, there is no widely-accepted definition to determine when the substrate
as been sufficiently modified. The development and use of substrate-driven end points might
ead to a change from empiric ablation patterns to a customized ablation strategy based on
trial physiology. In this paper, Katritsis and colleagues discuss specific procedural end points
s they pertain to ablation strategy.TRIAL FIBRILLATION2299Meta-Analysis Helps to Clarify the Role of RAS Inhibition in Preventing AFarkus P. Schneider, Tsushung A. Hua, Michael Böhm, Kristian Wachtell, Sverre E. Kjeldsen,
oland E. Schmieder
his study by Schneider and colleagues reviewed trial data on the effects of renin-angiotensin
ystem (RAS) inhibition for the prevention of atrial fibrillation (AF). Twenty-three
andomized controlled trials with more than 87,000 patients were included. Overall, RAS
nhibition reduced the odds ratio for AF by 33%, but there was substantial heterogeneity
etween trials. In patients with no history of AF, RAS inhibition was effective in heart failure
nd hypertensive patients with left ventricular hypertrophy, but not in post-myocardial
nfarction subjects. In secondary prevention, RAS inhibition reduced the odds for AF
ecurrence after cardioversion by 45%. This analysis supports the concept of RAS inhibition
s a treatment for primary and secondary prevention of AF.(continued on page A-21)
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MTRIAL FIBRILLATION2308Improved Long-Term Quality of Life After Ablation of AFnita Wokhlu, Kristi H. Monahan, David O. Hodge, Samuel J. Asirvatham, Paul A. Friedman,
homas M. Munger, David J. Bradley, Christine M. Bluhm, Janis M. Haroldson, Douglas L. Packer
okhlu and colleagues studied the relationship between atrial fibrillation (AF) ablation
fficacy and quality of life (QoL). In more than 300 patients with 2 years of follow-up, 72%
chieved AF control off anti-arrhythmic drugs (AADs), 15% achieved AF control on AADs,
nd 13% had recurrent AF. There were significant improvements in the median physical and
ental components of the Medical Outcomes Study Short Form-36 scores. Post-ablation
oL improvements were not different across 3 ablative efficacy outcomes. Independent
redictors of limited QoL improvement included higher baseline QoL, obesity, and warfarin
se at follow-up. AF ablation produces sustained QoL improvement at 2 years in patients
ith and without AF recurrence.ditorial Comment: Eric N. Prystowsky, Benzy J. Padanilam, p. 2317TRIAL FIBRILLATION2319Elevated BMI Predicts Short- and Long-Term Risk of AFsha B. Tedrow, David Conen, Paul M. Ridker, Nancy R. Cook, Bruce A. Koplan, JoAnn E. Manson,
ulie E. Buring, Christine M. Albert
edrow and colleagues used data from the Women’s Health Study to determine the
elationship between body mass index (BMI) and incident atrial fibrillation (AF) in women.
uring almost 13 years of follow-up in over 30,000 study participants, BMI was linearly
ssociated with AF risk. There was a 4.7% increase in risk with each kg/m2. When updated
easures of BMI were utilized to estimate dynamic risk, participants becoming obese during
ollow-up had a 41% adjusted increase in the risk of developing AF compared with those
aintaining a BMI 30 kg/m2. In this population of apparently healthy women, BMI was
ssociated with short- and long-term elevations in AF risk.ditorial Comment: Nikolaos Dagres, Maria Anastasiou-Nana, p. 2328TRIAL FIBRILLATION2330Effects of Ranolazine on Arrhythmias and Contractility in Human Atrial Tissueamuel Sossalla, Birte Kallmeyer, Stefan Wagner, Marek Mazur, Ulrike Maurer, Karl Toischer,
an D. Schmitto, Ralf Seipelt, Friedrich A. Schöndube, Gerd Hasenfuss, Luiz Belardinelli, Lars S. Maier
ossalla and colleagues used samples of right atrial tissue from patients undergoing
ardiovascular surgery to investigate changes in Na-currents (INa) related to permanent atrial
brillation (AF) and the effects of INa inhibition with ranolazine. Patch-clamp experiments in
solated atrial myocytes showed significantly reduced peak INa density in AF versus sinus
hythm (SR). In contrast, late INa was significantly increased in myocytes from AF atria.
anolazine reduced late INa by 60% in myocytes from patients with AF but only by 18%
n myocytes from SR atria. These findings suggest that ranolazine may be a promising new
reatment option for patients with atrial rhythm disturbances.
ditorial Comment: Ulrich Schotten, Sander Verheule, Benoit-Gilles Kerfant,
aura Greiser, p. 2343
(continued on page A-22)
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uTRIAL FIBRILLATION2346CAF Decreases I and I Differentially in Each Atriato1 Kur
icardo Caballero, Marta Gonza´lez de la Fuente, Ricardo Go´mez, Adriana Barana, Irene Amoro´s,
ablo Dolz-Gaito´n, BSCI, Lourdes Osuna, Jesús Almendral, Felipe Atienza, Francisco Ferna´ndez-Avilés,
na Pita, Jorge Rodrı´guez-Roda, Ángel Pinto, Juan Tamargo, Eva Delpo´n
aballero and colleagues compared the voltage-dependent K currents of human cells of the right
nd left atria to determine if electrical remodeling produced by chronic atrial fibrillation (CAF) is
hamber-specific. Currents were recorded using the whole-cell patch-clamp in myocytes from left
trial appendages (LAAs) and right atrial appendages (RAAs) obtained from patients with sinus
hythm (SR) or CAF undergoing cardiac surgery. The results showed that CAF reduced the
a2-independent 4-aminopyridine-sensitive component of the transient outward current (Ito1)
mplitude and density more markedly in the LAA than in the RAA. On the contrary, ultrarapid
omponent of the delayed rectifier current (IKur) was more markedly reduced in the RAA than in
he LAA. In both atria, CAF increased the amplitude and density of the slow component of the
elayed rectifier current. These results demonstrate that there are “intra-atrial” heterogeneities in
he repolarizing currents both in SR and CAF.ENTRICULAR TACHYCARDIA2355Characterization of the Arrhythmogenic Substrate in ICM and NICMhiro Nakahara, Roderick Tung, Rafael J. Ramirez, Yoav Michowitz, Marmar Vaseghi, Eric Buch,
ean Gima, Isaac Wiener, Aman Mahajan, Noel G. Boyle, Kalyanam Shivkumar
ate potentials (LP), commonly seen in post-infarction scars, reflect areas of myocardium
here conduction is slowed and interrupted by fibrosis; they are useful for targeting ablation
n patients with ischemic cardiomyopathy (ICM), but their prevalence and value as ablation
argets in patients with nonischemic cardiomyopathy (NICM) remains unknown. Nakahara
nd colleagues performed electroanatomic mapping, both endocardially and epicardially, in
atients with NICM and ICM. Mean total low voltage area was similar epicardially for ICM
nd NICM patients, but was nearly twice as large on the endocardial surface. An LP-targeted
blation strategy was 82% effective in ICM patients but only 50% effective in NICM patients.
he contribution of scar to the electrophysiological abnormalities targeted for ablation of
nstable ventricular tachycardia differs between ICM and NICM.(continued on page A-24)
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wENTRICULAR TACHYCARDIA2366Epicardial VT Ablation: A Multicenter Safety Studyrédéric Sacher, Kurt Roberts-Thomson, Philippe Maury, Usha Tedrow, Isabelle Nault, Daniel Steven,
eleze Hocini, Bruce Koplan, Lionel Leroux, Nicolas Derval, Jens Seiler, Matthew J. Wright,
aurence Epstein, Michel Haissaguerre, Pierre Jais, William G. Stevenson
onventional ablation techniques for ventricular tachycardia (VT) may fail when the re-entry
ircuits lie deep in the subendocardium or in the epicardium. Epicardial ablation can target
hese circuits; however, there is limited information about its safety. Sacher and colleagues
ompiled results from all patients undergoing VT ablation at 3 centers. Of 913 VT ablations,
7% involved epicardial mapping and/or ablation. Epicardial access was obtained via
ercutaneous subxyphoid puncture in the vast majority of the procedures. Five percent
uffered a major acute complication related to pericardial access: 7 patients had epicardial
leeding (80 ml) and 1 patient had coronary stenosis. Three delayed complications were
oted (1 major pericardial inflammatory reaction, 1 delayed tamponade, and 1 coronary
cclusion 2 weeks after the procedure).ditorial Comment: Henry H. Hsia, p. 2373ARDIAC PACEMAKERS/ICDs
2376eparin Bridging Significantly Increases
Bleeding Risks for Pacemaker/ICD Insertionhristine Tompkins, Alan Cheng, Darshan Dalal, Jeffrey A. Brinker, Charles T. Leng, Joseph E. Marine,
aman Nazarian, David D. Spragg, Sunil Sinha, Henry Halperin, Gordon F. Tomaselli, Ronald D. Berger,
ugh Calkins, Charles A. Henrikson
ompkins and colleagues measured the risk of significant bleeding complications in patients
ndergoing pacemaker or implantable cardioverter-defibrillator (ICD) implantation. Five
ercent of procedures resulted in a significant bleeding complication. Compared with controls
ot taking antiplatelet agents, the combination of aspirin and clopidogrel significantly
ncreased bleeding risk (7.2% vs. 1.6%). Use of periprocedural heparin markedly increased the
isk of bleeding to 14.3%, which was higher than the rate for patients taking warfarin, with
n international normalized ratio 1.5. These results suggest holding antiplatelet or
nticoagulation medications for a period of 3 to 5 days prior to device implantation for
atients at low risk for thromboembolic events, while patients at high risk should continue
arfarin throughout the periprocedural phase, avoiding the need for heparin “bridging.”(continued on page A-27)
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aCUTE MYOCARDIAL INFARCTION2383No Reflow in STEMI Patients Predicts 5-Year Mortalityjin Ndrepepa, Klaus Tiroch, Massimiliano Fusaro, Dritan Keta, Melchior Seyfarth, Robert A. Byrne,
ürgen Pache, Patricia Alger, Julinda Mehilli, Albert Schömig, Adnan Kastrati
drepepa and colleagues investigated the impact of no-reflow phenomenon on 5-year
ortality in patients with acute ST-segment elevation myocardial infarction (STEMI) treated
y primary percutaneous coronary intervention (pPCI). No-reflow phenomenon was
iagnosed in 29% of patients. Infarct size was 15% of the left ventricle in the no-reflow group
ompared with 8% in the reflow group. Those with no-reflow had a 2-fold greater risk of
eath during follow-up. In patients with STEMI treated by pPCI, no-reflow phenomenon
rovides prognostic information that is independent of and beyond that provided by infarct
ize.CUTE MYOCARDIAL INFARCTION2390Metabolic Syndrome Predicts Risk of MI Regardless of Ethnicityndrew Mente, Salim Yusuf, Shofiqul Islam, Matthew J. McQueen, Supachai Tanomsup, Churchill L. Onen,
umathy Rangarajan, Hertzel C. Gerstein, Sonia S. Anand, for the INTERHEART Investigators
ente and colleagues used data from the INTERHEART study to quantify the risk of acute
yocardial infarction (MI) conferred by the “metabolic syndrome” (MS). Over 26,000
ubjects from 52 countries were enrolled in this case-control study. The MS was associated
ith an increased risk of MI, both using the World Health Organization (odds ratio [OR]:
.69) and International Diabetes Federation (OR: 2.20) definitions. The associations were
irectionally similar across all regions and ethnic groups. The association with MI by the MS
as similar to that of diabetes (OR: 2.72) and hypertension (OR: 2.60). In this large-scale,
ultiethnic, international investigation, the risk of MI from MS is generally comparable tohat conferred by diabetes and hypertension.ORONARY ARTERY DISEASE2399IVUS Predicts Risk of Subsequent Cardiac Eventstephen J. Nicholls, Amy Hsu, Kathy Wolski, Bo Hu, Ozgur Bayturan, Andrea Lavoie, Kiyoko Uno,
Murat Tuzcu, Steven E. Nissen
lthough intravascular ultrasound (IVUS) has been used in clinical trials to evaluate the effect
f medical therapies on coronary atheroma progression, most of these studies have been too
mall to link these measurements with clinical events. Nicholls and colleagues combined
esults from 6 trials with serial IVUS imaging. A higher baseline percent atheroma volume
PAV) was associated with increased risk of myocardial infarction, coronary revascularization,
nd major adverse cardiovascular events (MACE) during follow-up. There was also a greater
ncrease in percent PAV in those who experienced a MACE. These data support the use of
therosclerosis imaging with IVUS in the evaluation of novel anti-atherosclerotic therapies.
